Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin

Acta Oncol. 1994;33(8):931-4. doi: 10.3109/02841869409098459.

Abstract

Eighty-one patients with metastatic or locally advanced colorectal cancer were treated at four oncological centers in Denmark with a regimen consisting of 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for 5 consecutive days every 4 weeks. The response rate was 21% among all 81 patients (CR 3, PR 14). The median survival was 10 months regardless of measurability, sex and location of disease. Toxicity was mild, 6 (7%) patients were excluded from the study due to gastrointestinal side-effects and 15 (19%) patients had the 5-FU dose reduced due to side-effects. The results are comparable to those of other studies using different doses of leucovorin.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Denmark
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Leucovorin / administration & dosage
  • Male
  • Middle Aged
  • Survival Analysis
  • Treatment Outcome

Substances

  • Leucovorin
  • Fluorouracil